Sagi-Dain L, Sagi-DainSinger A, Ben Shachar S, et al. - The risk of clinically significant chromosomal microarray analysis findings was determined in fetuses with nuchal translucency from 3.0–3.4 mm via performing this retrospective cohort study of all chromosomal microarray analysis tests conducted owing to a nuchal translucency measurement from 3.0–3.4 mm, without ultrasonographic anomalies, retrieved from the Israeli Ministry of Health computerized database. In addition, the yield of noninvasive prenatal testing (NIPT) was defined in such pregnancies. Overall, researchers identified 619 chromosomal microarray analyses conducted owing to isolated nuchal translucency from 3.0–3.4 mm. Clinically significant copy number variants were identified in 29 (4.7%) of these cases, suggesting a significantly higher risk compared with control-group pregnancies (relative risk 3.3). Outcomes overall suggest significantly higher rate of abnormal chromosomal microarray analysis findings in fetuses with nuchal translucency from 3.1–3.4 mm compared with fetuses with normal ultrasound findings.